FY2025 · ended Dec 31, 2025 · Revenue $7.70M, +0.1% YoY · Filed Mar 12, 2026
Bolt Biotherapeutics, Inc. (BOLT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $7.7 million and a net loss of $33.4 million. Free cash flow was -$39.9 million. As of Jun 30, 2026 it held $18.1 million in cash and investments and $21.6 million in total debt.
Revenue (TTM)
$4.70M
+12.8% vs year-ago TTM
Net income (TTM)
$-28.74M
+43.3% vs year-ago TTM
Operating cash flow (TTM)
$-31.45M
+38.8% vs year-ago TTM
Free cash flow
$-39.92M
+34.9% vs prior year
EPS (TTM)
$-16.37
+38.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
1.92M
-95.0% vs prior year
Net cash
$-3.52M
as of Jun 30, 2026
Operating margin
-654.5%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BOLT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Redwood City, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1641281
- Former names
- Bolt Therapeutics, Inc. (until May 7, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.7M | $7.7M | $7.9M | $5.7M | $1.3M |
| Operating income | -$36.1M | -$73.0M | -$76.2M | -$90.3M | -$92.8M |
| Net income | -$33.4M | -$63.1M | -$69.2M | -$88.1M | -$98.6M |
| Diluted EPS | -$17.85 | -$33.06 | -$1.83 | -$2.36 | — |
| Operating cash flow | -$39.9M | -$61.3M | -$69.5M | -$76.5M | -$57.1M |
| Free cash flow | -$39.9M | -$61.3M | -$69.7M | -$78.5M | -$59.4M |
| Total assets | $56.7M | $99.6M | $159.8M | $227.8M | $307.7M |
| Total liabilities | $30.2M | $42.4M | $47.0M | $56.3M | $57.6M |
| Stockholders' equity | $26.5M | $57.2M | $112.7M | $171.5M | $250.1M |
| Cash and investments | $31.8M | $70.2M | $128.6M | $192.8M | $271.6M |
| Total debt | $23.0M | $25.2M | $20.2M | $22.6M | $24.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Agreement ended, Acquisition or sale of assets, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 6, 2026 | Oct 1, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 11, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
All 294 Bolt Biotherapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.